RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

Trial Identifier: D4191R00028
Sponsor: AstraZeneca
NCTID:: NCT05933044
Start Date: November 2021
Primary Completion Date: August 2022
Study Completion Date: August 2022
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Canada, Alberta Calgary, Alberta, Canada, T2N 1N4
Canada, British Columbia Vancouver, British Columbia, Canada, V5Z 4E6
Canada, Nova Scotia Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec Montreal, Quebec, Canada, H2X 3E4